share_log

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Benzinga ·  Jul 12, 2023 17:59

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment